Yi, Jae-Sung Perla, Sravan Huang, Yan Mizuno, Kana Giordano, Frank J Vinks, Alexander A Bennett, Anton M
Published in
Cardiovascular drugs and therapy
Noonan syndrome with multiple lentigines (NSML) is an autosomal dominant disorder presenting with hypertrophic cardiomyopathy (HCM). Up to 85% of NSML cases are caused by mutations in the PTPN11 gene that encodes for the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP2). We previously showed that low-dose dasatinib protec...
Wang, Fen Jin, Feng Cheng, Boran Zhang, Yue Zhou, Qing Wang, Shubin
Published in
Journal of cancer research and clinical oncology
Anlotinib is an anti-angiogenetic multi-targeted tyrosine kinase inhibitor. This study aimed to evaluate the efficacy and safety of anlotinib in advanced non-small cell lung cancer (aNSCLC) in the real world. Patients with aNSCLC receiving anlotinib were enrolled in two cohorts (treatment naive and previously treated). The endpoints included progre...
Tullemans, Bibian M. E. Brouns, Sanne L. N. Swieringa, Frauke Sabrkhany, Siamack van den Berkmortel, Franchette W. P. J. Peters, Natascha A. J. B. de Bruijn, Peter Koolen, Stijn L. W. Heemskerk, Johan W. M. Aarts, Maureen J. B.
...
Published in
BMC Cancer
Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the TKI sunitinib affected quantitative and qualitative platelet traits as a function of the sunitinib level and t...
Fogueri, Uma Charkoftaki, Georgia Roda, Gavriel Tuey, Stacey Ibrahim, Mustafa Persaud, Indushekhar Wempe, Michael F Brown, Jared M Thurman, Joshua M Anchordoquy, Thomas J
...
Published in
Drug delivery and translational research
Studies have suggested imatinib mesylate (ImM) as a potential treatment for systemic lupus erythematosus nephritis (SLEN). However, ImM has limited renal excretion. The goal of the current research was to develop an ImM containing nanoformulation, conduct studies to evaluate pharmacokinetics, and determine whether kidney deposition can be enhanced ...
Hirayama, Akihiro Sorimachi, Takatoshi Yokota, Kazuma Shigematsu, Hideaki Srivatanakul, Kittipong Matsumae, Mitsunori
Published in
Acta neurochirurgica
New-generation tyrosine kinase inhibitors (TKIs), nilotinib and ponatinib, for chronic myelogenous leukemia (CML) have been reported to cause symptomatic cerebral ischemia. Herein, we report two patients with asymptomatic cerebral artery stenosis associated with these TKIs, as a previously unreported finding. Both patients were in their 40 s and ad...
Lu, Shun Zhou, Qing Liu, Xiaoqing Du, Yingying Fan, Yun Cheng, Ying Fang, Jian Lu, You Huang, Cheng Zhou, Jianying
...
Published in
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Lorlatinib was found to have activity in ALK-positive NSCLC in a global phase 1 and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive advanced or metastatic NSCLC. Open-label, dual-cohort study (NCT03909971); patients had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib...
Field, Matthew G Boldt, H Culver Abu Hejleh, Taher Binkley, Elaine M
Published in
American journal of ophthalmology case reports
Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. A 68-year-old man presented with an amelanotic choroidal lesion in the left eye concerning ...
Kim, Se Jeong Kim, Tae Eun Jee, Byung Chul
Published in
Clinical and Experimental Reproductive Medicine
Objective The impact of imatinib, a tyrosine kinase inhibitor, on ovarian follicles and several proteins related to follicular function and apoptosis was investigated in mice. Methods Saline, cyclophosphamide (Cp; 50 or 75 mg/kg), or imatinib (7.5 or 15 mg/kg) was injected once intraperitoneally into female B6D2F1 mice (18 mice in each group). In m...
Yamada, Shinya Arita, Kotaro Kondo, Yukio Mizuta, Shuichi Okumura, Hirokazu
Published in
Case Reports in Oncology
Chronic myeloid leukemia (CML) blast phase (monocytic lineage) is extremely rare. A 39-year-old Japanese man was diagnosed with CML blast phase (monocytic lineage). T315I mutation was positive, ponatinib was initially started, and then, allogenic hematopoietic stem cell transplantation (allo-HSCT) was performed. Seven days after allo-HSCT, hyper-ac...
Zhang, Na Jiang, Ting-De Yi, Shu-Hua
Published in
World Journal of Clinical Cases
BACKGROUND Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder. Plasma cell dyscrasias are a rare heterogeneous group of hematological disorders. The co-occurrence of CML and plasma cell dyscrasias in the same patient is an extremely rare incident and has been reported in several cases in the literature. CASE SUMMARY In the ...
